Gene organization and evolution history
=======================================

The *presenilin 1* (PS1) gene on human chromosome 14 (14q24.3) was initially discovered by genetic analysis of a subset of pedigrees in which the Alzheimer\'s disease is transmitted as a pure autosomal dominant trait \[[@B1]\]. The closely related *PS2* gene on chromosome 1 (1q42.2) was identified subsequently by sequence homology \[[@B2],[@B3]\]. Both *PS1* and *PS2* genes are organized into ten translated exons that display tissue-specific alternative splicing \[[@B2],[@B4],[@B5],[@B6],[@B7]\]. The functions and biological importance of differentially spliced presenilin variants are poorly understood; differential expression of isoforms may lead to differential regulation of the proteolytic processing of the β-amyloid precursor protein (βAPP; see later). For example, aberrant *PS2* transcripts lacking exon 5 increase the rate of production of amyloid β peptide (Aβ, the neurotoxic peptide implicated in Alzheimer\'s disease) \[[@B8]\], whereas naturally occurring isoforms without exons 3 and 4 and/or without exon 8 do not affect production of Aβ \[[@B6],[@B9]\].

GenBank database searches using the full length *PS1* sequence suggest that presenilin-like proteins are phylogenetically ancient and well-conserved across diverse eukaryote species, including plants, molluscs, insects, fish, birds, and mammals \[[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16]\]. Functional conservation of presenilins in most non-human species is undetermined, except in the nematode *Caenorhabditis elegans,* in which a deficiency in *Sel-12,* the *PS1* homolog, induces an egg-laying defect that can be rescued by expression of human *PS1* \[[@B17],[@B18]\]. Additional presenilin homologs were recently identified in disparate eukaryotes by their homology to the PS1 transmembrane domains, suggesting that the presenilin family may be more common than previously contemplated \[[@B19],[@B20]\].

Characteristic structural features
==================================

Mammalian PS1 and PS2 are synthesized as 50 kDa polypeptides, each predicted to traverse the membrane 6-10 times; the ammo and carboxyl termini are both oriented towards the cytoplasm \[[@B21]\]. The current model, with eight transmembrane domains, is shown in Figure [1](#F1){ref-type="fig"}. More than 100 different missense mutations and two splicing-defect mutations in the *PS1* gene have been reported (Table [1](#T1){ref-type="table"}) \[[@B22],[@B23]\]. These are dispersed throughout the *PS1* sequence, with the majority of mutations clustered near membrane interfaces in the highly conserved transmembrane domains or in hydrophobic residues in either the amino-terminal domain or the putative loop domain between transmembrane domains 6 and 7.

Following synthesis, the PS1 and PS2 holoproteins undergo tightly regulated, but imprecise, endoproteolysis in their third cytoplasmic loop domain to generate an approximately 35 kDa amino-terminal fragment and an 18-20 kDa carboxy-terminal fragment, which remain associated with each other \[[@B24]\]. It is clear that cleavage of presenilins following export from the endoplasmic reticulum is governed by additional rate-limiting factors, such as nicastrin (see below), because overexpressed presenilins readily saturate the processing machinery and accumulate as holoproteins \[[@B25]\]. An additional proteolytic pathway is known to involve members of the caspase 3 family of proteases and may be involved in apoptosis \[[@B26]\].

Localization and function
=========================

Human *PS1* and *PS2* have distinct patterns of expression in human tissues. Whereas *PS1* is transcribed uniformly throughout the brain and in peripheral tissues, the *PS2* transcript is expressed at relatively low levels in the brain, except in the corpus collosum, where it is high; it is highly expressed in some peripheral tissues, such as pancreas, heart, and skeletal muscle \[[@B27]\]. The low PS2 levels in brain and the compensatory activity provided by PS1 may explain why *PS2* mutations are infrequent and incompletely penetrant compared with *PS1* mutations, which are fully penetrant \[[@B28],[@B29]\].

The βAPP protein is cleaved by three different activities, called α-, β- and γ-secretases, to generate Aβ and other fragments. Members of the Notch family, which are involved in developmental signaling in many animals, undergo cleavage at a site (S3) within the transmembrane domain to release an intracellular domain (NICD). It is well established that presenilins are required for the γ-secretase cleavage of βAPP and for the S3 cleavage of Notch-family receptors \[[@B30]\]. For βAPP processing, γ-secretase cleavage is the final step of two distinct proteolytic pathways involving either an α-secretase - which precludes Aβ peptide formation - or a β-secretase, which releases the Aβ peptide, comprising the 40 or 42 carboxy-terminal residues of βAPP. It is uncertain whether the γ-secretase cleavage event occurs at the plasma membrane or during trafficking of βAPP. The usual downstream effect of presenilin mutations in individuals with presenilin-linked familial Alzheimer\'s disease is the accumulation of Aβ in the brain \[[@B31],[@B32]\] and a shift in the site of the γ-secretase cleavage of βAPP to produce the longer Aβ peptide, spanning residues 1-42 (Aβ42). These main features can be recapitulated in cell culture or in animal models expressing mutant forms of PS1 \[[@B33],[@B34],[@B35]\]. Conversely, PS1-deficient mice are impaired in γ-secretase activity, have reduced Aβ secretion, and accumulate γ-secretase substrates (the carboxy-terminal βAPP fragments derived from α- and β-secretase processing; see Figure [2](#F2){ref-type="fig"}) \[[@B36]\].

Mutation of two highly conserved aspartate residues in the transmembrane domains of PS1 (Asp257 and Asp385, shown in blue in Figure [1](#F1){ref-type="fig"}) inactivates γ-secretase activity and reduces Aβ secretion \[[@B37]\]. The sequence motif around Asp385 is somewhat similar to a sequence within prepilins, a family of bacterial peptidases \[[@B38]\]; this has promoted speculation that presenilins are themselves aspartyl proteases responsible for γ-secretase activity and that the critical Asp257 and Asp385 residues form that catalytic center of the γ-secretase. Additional support for the idea that presenilins are the proteases that have γ-secretase activity comes from studies in which photoactivated inhibitors of γ-secretase activity were found to bind to PS1 and PS2 \[[@B39],[@B40]\].

It should be noted that forms of PS1 with the D257A or D385A mutations integrate poorly into the heteromeric complexes that are considered necessary for γ-secretase function, raising the possibility that these transmembrane-domain mutations disable PS1 structurally \[[@B41]\]. Moreover, several lines of evidence show that the regulation of βAPP and Notch cleavage differs, however, and such evidence is difficult to reconcile with a direct enzymatic role for PS1 in γ-secretase cleavage. First, a naturally occurring splice variant of PS1 lacking the region (encoded by exon 8) that contains the critical Asp257 allows Aβ production but not cleavage of Notch \[[@B42]\]. Second, different presenilin mutations differentially affect Aβ production and Notch cleavage \[[@B43],[@B44],[@B45]\]. Third, some recently discovered γ-secretase inhibitors preferentially affect processing βAPP over that of Notch \[[@B46]\]. Together, these findings suggest the presenilins regulate proteolysis indirectly, perhaps by an effect on trafficking of βAPP or Notch or by activation of the γ-secretase.

The biological purpose of presenilin-dependent γ-secretase cleavage of βAPP is still unknown. By analogy with the signaling pathway downstream of cleaved Notch and NICD, recent studies have raised the intriguing possibility that the short-lived carboxyl-terminal stub of βAPP, called (βAPP intracellular domain (AICD), is released into the cytoplasm following γ-secretase cleavage and translocates to the nucleus (Figure [2](#F2){ref-type="fig"}), where it may regulate expression of components involved in mobilizing intracellular calcium stores \[[@B47],[@B48],[@B49]\]. Another proposal implicates βAPP as a regulator of the axonal transport of a subset of vesicles ferrying cargo to nerve terminals. This view is derived from the observations that βAPP interacts directly with the light chain of the transport protein kinesin \[[@B50]\], that the transport of a vesicular compartment containing PS1 and γ-secretase depends on βAPP \[[@B51]\], and that deletion of the *Drosophila* βAPP-like gene (dAPPL) or overexpression of either dAPPL or human (βAPP in *Drosophila* disrupts axonal transport \[[@B52],[@B53]\]. In this scheme, γ-secretase cleavage of the βAPP by presenilin-containing complexes releases the carboxy-terminal portion of (βAPP that connects the transport vesicle to the transport machinery through interaction with kinesin, thereby disengaging the vesicle from microtubules upon arrival at its destination. Thus, presenilins may influence diverse cellular processes, such as intracellular signaling and axonal traffic.

*In vitro* studies of detergent-solubilized membranes show that γ-secretase activity resides within large multisubunit complexes that also contain presenilins. If presenilin molecules are excluded from these complexes, they are rapidly targeted for proteosome-mediated degradation \[[@B54]\]. On density gradients, presenilin holoproteins and the amino-and carboxy-terminal fragments of presenilins co-elute with high-molecular-weight markers (180 kDa for the holoproteins and 250-1000 kDa for the fragments \[[@B25],[@B55]\]), presumably because they are part of larger complexes, and antibodies to PS1 coimmunoprecipitate heteromeric protein complexes that contain γ-secretase activity \[[@B56]\]. Conversely, affinity isolation with γ-secretase inhibitors co-purifies protein complexes containing PS1 \[[@B39],[@B40]\]. Members of the Armadillo protein family (β- and δ-catenin, neural plakophilin-related armadillo protein (NPRAP), and p0071) \[[@B55],[@B57],[@B58]\] interact with presenilins but are not required for γ-secretase activity *in vitro* \[[@B40]\]. Other interactions whose role in γ-secretase activity is unknown have been reviewed previously \[[@B22]\].

More recently, PS1 and PS2 were found to interact with nicastrin, a novel single-pass transmembrane protein that is essential for processing of βAPP and Notch \[[@B59],[@B60],[@B61]\]. Nicastrin is clearly an important regulator of γ-secretase activity: nicastrin antibodies immunoprecipitate both presenilin and the active γ-secretase complex \[[@B40]\], and missense or deletion mutations within a conserved lumenal domain of nicastrin up- or down-regulate Aβ production in a manner that corresponds with PS1 binding, suggesting that γ-secretase activity is generated only after an obligatory interaction between nicastrin and PS1 \[[@B59]\]. Notch cleavage is affected similarly by nicastrin mutations, albeit to a lesser extent \[[@B60]\]. Moreover, nicastrin is essential for the normal processing of both βAPP and Notch homologs in *Drosophila* and *C. elegans,* and human nicastrin can partially rescue mutants of the *C. elegans* nicastrin homolog Aph-2 \[[@B59],[@B61],[@B62],[@B63],[@B64]\], suggesting that nicastrin function and its interactions with presenilins are conserved widely in non-mammalian species. Only mature glycosylated nicastrin that has passed through the Golgi compartment interacts with PS1 and is included in γ-secretase complexes \[[@B65]\]; overexpressed nicastrin fails to mature normally and accumulates within the endoplasmic reticulum. Moreover, entry of each of nicastrin and PS1 into γ-secretase complexes appears to be regulated by the other protein: the loss of one partner destabilizes the other \[[@B61],[@B63],[@B66],[@B67]\].

Two potential new members of the PS-nicastrin complexes are homologs of Aph-1 and Pen-2, components of the *C. elegans* Glp-1/Notch signaling cascade that interact genetically with Sel-12/presenilin and Aph-2/nicastrin \[[@B68],[@B69]\]. Primary sequence analysis suggests that Aph-1 and Pen-2 have seven and two membrane spanning domains, respectively, that are conserved in their respective *Drosophila* and human homologs. Human Aph-1 and Pen-2 can rescue *C. elegans* mutants lacking their homologs only when both transgenes are present together, implying that they act in concert. Moreover, reduction of Aph-1 and Pen-2 expression in *Drosophila* cells by RNA inhibition reduces γ-secretase activity \[[@B69]\]. Reduced expression of nematode Aph-1 causes mislocalization of Aph-2/nicastrin \[[@B68]\], and both Aph-1 and Pen-2 are required to maintain presenilin levels \[[@B69]\], suggesting that they regulate, or are components of, the presenilin-nicastrin γ-secretase complexes.

Frontiers
=========

The identification of the additional γ-secretase components within the presenilin complexes is clearly an important task that lies ahead. The complexes purified to date are quite large, partly because of membrane impurities that remain associated following treatment with gentle detergents and partly because of interacting proteins that are not related to γ-secretase activity but are necessary for trafficking and maturation of the complex. The genetic cause of at least half of all cases of early onset familial Alzheimer\'s disease remain unexplained, and some of the unknown genes may have products that may modulate presenilin activity within γ-secretase complexes.
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![A molecular model of Presenilin-1. The protein is thought to have eight transmembrane domains. Residues associated with mutations found in familial Alzheimer\'s disease are colored as indicated in the key. \'Endoproteolysis\' indicates the approximate site of the imprecise cleavage of the molecule.](gb-2002-3-11-reviews3014-1){#F1}

![The role of presenilins in the γ-secretase cleavage of Notch and βAPP. Notch is cleaved by tumor necrosis factor α converting enzyme (TACE), and its ligand binds to the part of Notch that remains attached to the membrane. βAPP is cleaved by either the γ-secretase pathway or the γ-secretase pathway to give a membrane-bound carboxy-terminal fragment (APP-CTF). Subsequent γ-secretase cleavage (in the transmembrane domain) of Notch or APP-CTF produces carboxy-terminal intracellular domains, NICD and AICD, respectively, which enter the nucleus and are thought to regulate gene expression. The γ-secretase cleavage of βAPP also produces the neurotoxic Aβ peptide, but only if βAPP has been first cleaved by γ-secretase (not γ-secretase). The γ-secretase complex includes, in addition to PS1, the presenilin-binding protein nicastrin; members of the Armadillo protein family, such as β-catenin, have also been detected in presenilin complexes, although their role is not understood. Aph-1 and Pen-2 may also participate in the γ-secretase complex.](gb-2002-3-11-reviews3014-2){#F2}

###### 

Mutations in the presenilin genes

  *PS1*                                                              
  ------------------ ------------------------- --------------------- ---------------------------------------
  Codon              Location                  Mutation              Phenotype
                                                                     
  35                 Amino-terminal domain     Arg→Gln               FAD
  79                 Amino-terminal domain     Ala→Val               FAD, onset 64 years
  82                 TM1                       Val→Leu               FAD, onset 55 years
  94                 TM1                       Val→Met               See \[[@B71]\]
  96                 TM1                       Val→Phe               FAD, onset 53 years
  105                TM1/TM2 loop              Phe→Leu               FAD, onset 52 years
  113-114 (insert)   TM1/TM2 loop              Insert Thr            FAD, onset 35 years
  115                TM1/TM2 loop              Tyr→His               FAD, onset 37 years
  115                TM1/TM2 loop              Tyr→Cys               FAD, onset 42 years
  116                TM1/TM2 loop              Thr→Asn               FAD, onset 37 years
  117                TM1/TM2 loop              Pro_Leu               AD, onset 28 years
  120                TM1/TM2 loop              Glu_Asp               FAD, onset 48 years
  120                TM1/TM2 loop              Glu_Lys               FAD, onset 37 years
  123                TM1/TM2 loop              Glu_Lys               FAD, onset 56-62 years
  135                TM2                       Asn_Asp               FAD, onset 36 years
  139                TM2                       Met_Thr               FAD, onset 49 years
  139                TM2                       Met_Val               FAD, onset 40 years
  139                TM2                       Met_Ile               AD
  139                TM2                       Met_Lys               FAD, onset 37 years
  143                TM2                       Ile_Thr               FAD, onset 35 years
  143                TM2                       Ile_Phe               FAD, onset 55 years
  146                TM2                       Met_Leu               FAD, onset 45 years
  146                TM2                       Met_Val               FAD, onset 38 years
  146                TM2                       Met_Ile               FAD, onset 40 years
  147                TM2                       Thr_Ile               FAD, onset 42 years
  156 + insert       TM3 interface             Tyr\_ (Phe,Ile,Tyr)   FAD
  163                TM3 interface             His_Arg               FAD, onset 50 years
  163                TM3 interface             His_Tyr               FAD, onset 47 years
  165                TM3                       Trp_Cys               FAD, onset 42 years
  169                TM3                       Ser_Leu               FAD, onset 31 years
  169                TM3                       Ser_Pro               FAD, onset 35 years
  171                TM3                       Leu_Pro               FAD, onset 40 years
  173                TM3                       Leu_Trp               FAD, onset 27 years
  177                TM3                       Phe_Ser               FAD
  178                TM3                       Ser_Pro               FAD
  184                TM3                       Glu_Asp               FAD
  206                TM4                       Gly_Ser               FAD
  209                TM4                       Gly_Val               FAD, onset 30-48 years
  209                TM4                       Gly_Arg               FAD, onset 49 years
  213                TM4 interface             Ile_Thr               FAD, onset 42-48 years
  213                TM4 interface             Ile_Leu               FAD
  219                TM4 interface             Leu_Pro               FAD
  219                TM4 interface             Leu_Phe               See \[[@B71]\]
  222                TM5                       Gln_Arg               FAD
  231                TM5                       Ala_Thr               FAD, onset 52 years
  231                TM5                       Ala_Val               FAD
  233                TM5                       Met_Thr               FAD, onset 35 years
  233                TM5                       Met_Leu               FAD, onset 46 years
  235                TM5                       Leu_Pro               FAD, onset 32 years
  237                TM5                       Phe_Ile               AD with spastic paraparesis, 31 years
  246                TM6                       Ala_Glu               FAD, onset 55 years
  250                TM6                       Leu_Ser               FAD, onset 53 years
  260                TM6                       Ala_Val               FAD, onset 40 years
  261                TM6                       Val_Phe               FAD
  262                TM6                       Leu_Phe               FAD, onset 50 years
  263                TM6/TM7 loop              Cys_Arg               FAD, onset 47 years
  264                TM6/TM7 loop              Pro_Leu               FAD, onset 45 years
  267                TM6/TM7 loop              Pro_Ser               FAD, onset 35 years
  269                TM6/TM7 loop              Arg_Gly               FAD, onset 47 years
  269                TM6/TM7 loop              Arg_His               FAD, onset 47 years
  273                TM6/TM7 loop              Glu_Ala               FAD, onset 63 years
  274                TM6/TM7 loop              Thr_Arg               FAD
  278                TM6/TM7 loop              Arg_Thr               FAD, onset 37 years
  280                TM6/TM7 loop              Glu_Ala               FAD, onset 47 years
  280                TM6/TM7 loop              Glu_Gly               FAD, onset 42 years
  282                TM6/TM7 loop              Leu_Arg               FAD, onset 43 years
  285                TM6/TM7 loop              Ala_Val               FAD, onset 50 years
  286                TM6/TM7 loop              Leu_Val               FAD, onset 50 years
  290                TM6/TM7 loop              Ser\>Cys              FAD, onset 39-50 years
  291-319 deletion   TM6/TM7 loop              Shortened loop        FAD
  352 (insert)       TM6/TM7 loop              Insert Arg            FAD
  354                TM6/TM7 loop              Thr_Ile               FAD
  358                TM6/TM7 loop              Arg_Gln               FAD
  365                TM6/TM7 loop              Ser_Tyr               FAD
  378                TM7                       Gly_Glu               FAD, onset 35 years
  384                TM7                       Gly_Ala               FAD, onset 35 years
  390                TM7                       Ser_Ile               FAD, onset 39 years
  392                TM7                       Leu_Val               FAD, onset 25-40 years
  394                TM7                       Gly_Val               FAD
  405                TM7/TM8 loop              Asn_Ser               FAD, onset 48 years
  409                TM8                       Ala_Thr               FAD, onset 58 years
  410                TM8                       Cys_Tyr               FAD, onset 48 years
  418                TM8                       Leu_Phe               FAD
  424                TM8                       Leu_Arg               FAD, onset 33 years
  426                TM8                       Ala_Pro               FAD, onset 48-60 years
  431                Carboxy-terminal domain   Ala_Glu               FAD
  434                Carboxy-terminal domain   Ala_Cys               FAD
  435                Carboxy-terminal domain   Leu_Phe               FAD
  436                Carboxy-terminal domain   Pro_Ser               FAD, onset 48-60 years
  436                Carboxy-terminal domain   Pro_Gln               FAD, onset 48-60 years
  439                Carboxy-terminal domain   Ile_Val               FAD
                                                                     
  *PS2*                                                              
                                                                     
  Codon              Location                  Mutation              Phenotype
                                                                     
  62                 N-term                    Arg_His               AD, onset 62 years
  122                TM1/TM2 loop              Thr_Pro               FAD, onset 46 years
  141                TM2                       Asn_Ile               FAD, onset 50-65 years
  148                TM2                       Val_Ile               AD, Onset 71 years
  239                TM5                       Met_Val               FAD, onset variable 45-
  84 yrs                                                             
  239                TM5                       Met_Ile               FAD, onset 58 years

Compiled from \[[@B2],[@B70],[@B71]\]. Abbreviations: AD, Alzheimer\'s disease; FAD,familial Alzheimer\'s disease; TM, transmembrane segment; TM1/TM2 loop, the loop between transmembrane segments 1 and 2. The age of onset of disease is given if it is known.
